Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View

Author(s): Roberta Filograna, Mariano Beltramini, Luigi Bubacco, Marco Bisaglia

Journal Name: Current Neuropharmacology

Volume 14 , Issue 3 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Parkinson’s disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the Substantia Nigra. The pathogenesis of this disorder remains poorly understood and PD is still incurable. Current drug treatments are aimed primarily for the treatment of symptoms to improve the quality of life. Therefore, there is a need to find out new therapeutic strategies that not only provide symptomatic relief but also halt or reverse the neuronal damage hampering PD progression. Oxidative stress has been identified as one of the major contributors for the nigral loss in both sporadic and genetic forms of PD. In this review we first evaluate the current literature that links oxidative stress and mitochondrial dysfunction to PD. We then consider the results obtained through the treatment of animal models or PD patients with molecules that prevent oxidative stress or reduce mitochondrial dysfunction.

Keywords: Antioxidants, iron chelators, mitochondria, oxidative stress, radical scavengers, reactive oxygen species.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 29 October, 2015
Page: [260 - 271]
Pages: 12
DOI: 10.2174/1570159X13666151030102718
Price: $65

Article Metrics

PDF: 19
PRC: 1